Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
NCT03247712Phase 2Active, not recruiting
- Start
- Jan 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (4 cohorts). Primary endpoint: Number of patients with an Unplanned Delay to Surgery at 6 weeks. Started Jan 2018; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03247712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247712.